Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 15;7(9):6141-8.
eCollection 2014.

Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer

Affiliations

Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer

Kyungtae Ko et al. Int J Clin Exp Pathol. .

Abstract

The long-term mortality risk from prostate cancer increases in lymph node (LN) positive patients. This study was done to assess the effect of lymph node Gleason score (LNGS) on prognosis in patients with LN-positive prostate cancer. Among the 1,415 patients who received pelvic lymph node dissection (PLND), 117 (8.4%) patients had a positive LN. The PGS of the prostate specimens and the LNGS of the positive LNs were assessed by uropathologists. The median age of patients at surgery was 67 years (interquartile range [IQR], 62-71 years) and the median follow-up duration was 44.3 months (IQR, 27.0-78.5 months). Pathologic Gleason scores (PGS) of 6-9 included one (0.9%), 53 (49.5%), 22 (20.6%), and 31 (29.0%) patients. The median total number of retrieved LNs was 9.0 (IQR, 5.3-12.8). The median number of positive LNs was one (IQR, 1-2). Cancer architecture with a Gleason pattern and score were observed in LNs as in ordinary prostate specimens. LNGS 6-9 included nine (8.1%), 57 (51.4%), 31 (27.9%), and 14 (12.6%) patients. The speaman's analysis showed the meaningful correlation between PGS and LNGS (P = 0.249, P = 0.011). The univariate analysis showed that the number of positive LNs and LNGS were significantly associated with prostate cancer-specific survival (P = 0.028; P = 0.005). The same architecture that is seen in the prostate was seen in positive LNs, and LNGS may be a significant prognostic factor in patients with LN-positive prostate cancer.

Keywords: Gleason score; lymph node metastasis; prognosis; prostate cancer; radical prostatectomy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Metastatic prostatic adenocarcinoma in the lymph node showing cribriform gland formation (Gleason score 8 (4+4)). (A) A low power scan. Left lower; positive lymph node, right upper; normal lymph node. (B) Higher magnification of (A) (Original magnification in (A), ×1.25 and (B) ×200).
Figure 2
Figure 2
Examinations of metastatic carcinoma. A. Metastatic adenocarcinoma in lymph nodes showing Gleason score 6 (double sum of pattern 3). Well formed glands are observed in lymphoid tissue. (Original magnification = ×200). B. Metastatic adenocarcinoma in lymph nodes showing Gleason score 7 (pattern 4 and pattern 3). Both discrete gland formation and ill defined glandular unit are observed in lymphoid tissue. (Original magnification = ×200). C. Metastatic adenocarcinoma in lymph nodes showing Gleason score 8 (double sum of pattern 4). The large cribriform glands are observed in lymphoid tissue. (Original magnification = ×200). D. Metastatic adenocarcinoma in lymph nodes showing Gleason score 9 (pattern 4 and pattern 5). Poorly differentiated gladular cells with solid proliferation or single cell infiltration is observed in lymphoid tissue. (Original magnification = ×200).

References

    1. National cancer information center web site. 2009. http://www.cancer.go.kr/ncic/cics_f/01/012/index.html.
    1. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178:864–870. discussion 870-861. - PubMed
    1. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009;55:1251–1265. - PubMed
    1. Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer. 1999;86:657–663. - PubMed
    1. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974. - PubMed

MeSH terms

LinkOut - more resources